Optiver Holding B.V. Genmab A/S Transaction History

Optiver Holding B.V.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$35.27 - $42.24 $346,492 - $414,965	9,824 New	9,824 $346,000
Q1 2023 May 11, 2023	BUY	$34.88 - $43.22 $3.36 Million - $4.16 Million	96,269 New	96,269 $3.64 Million
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $3.02 Million - $35.8 Million	95,826 Added 251.17%	133,978 $4.31 Million
Q2 2022 Aug 10, 2022	SELL	$26.83 - $38.57 $945,784 - $1.36 Million	-35,251 Reduced 48.02%	38,152 $1.24 Million
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $947,596 - $1.21 Million	-30,617 Reduced 29.43%	73,403 $2.66 Million
Q4 2021 Feb 14, 2022	BUY	$35.87 - $47.12 $2.4 Million - $3.15 Million	66,910 Added 180.3%	104,020 $4.12 Million
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $1.54 Million - $1.81 Million	37,110 New	37,110 $1.62 Million
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $2.67 Million - $3.61 Million	-81,058 Closed	0 $0
Q1 2021 May 20, 2021	SELL	$30.92 - $44.4 $17.8 Million - $25.6 Million	-576,644 Reduced 87.68%	81,058 $2.66 Million
Q1 2021 May 14, 2021	BUY	$30.92 - $44.4 $20.3 Million - $29.2 Million	657,702 New	657,702 $21.6 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Optiver Holding B.V., based on Form 13F filings with the SEC.

Stay updated on Optiver Holding B.V. with notifications on news.